Bristol Myers Squibb (BMS) presented 18 analyses at the 66th American Society of Hematology (ASH) Annual Meeting, showcasing the efficacy, durability, and safety of their current cell therapies for blood cancers, along with promising pipeline data for future indications, including autoimmune diseases. The presented data highlighted advancements in blood cancers and beyond, reaffirming BMS’s commitment to cell therapy innovation. This research aims to improve treatment outcomes and expand therapeutic options for patients with various hematological malignancies and autoimmune conditions.
These findings are crucial for the field of hematology and oncology, offering potential advancements in the treatment of challenging cancers and autoimmune diseases. The five-year survival data for Breyanzi in lymphoma patients, coupled with new data on its effectiveness in earlier treatment lines and real-world settings, strengthens its position as a key therapeutic option. The introduction of a novel GPRC5D-targeted CAR T therapy, arlo-cel, offers a potential first-in-class treatment for heavily pre-treated multiple myeloma patients, addressing a significant unmet need. Further, the progress with CD19 NEX-T in autoimmune diseases like lupus suggests a possible one-time treatment for sustained remission, opening new avenues for managing these chronic conditions.
Key data presented include: five-year overall survival data for Breyanzi (liso-cel) in relapsed or refractory large B-cell lymphoma (LBCL) with an estimated OS rate of 38% at five years; ctDNA data from the TRANSFORM study supporting its use as an early predictor of durable clinical benefit after second-line LBCL treatment with Breyanzi; real-world data supporting Breyanzi’s use in second-line LBCL regardless of age and in patients with sCNS involvement; two-year follow-up data showing high ORR and CR rates for Breyanzi in relapsed or refractory follicular lymphoma; promising primary analysis results for Breyanzi plus ibrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma; a high manufacturing success rate for Abecma demonstrating its commercial reliability; first OS and PFS data for the GPRC5D-targeted CAR T therapy arlo-cel in relapsed or refractory multiple myeloma, showing durable responses and a manageable safety profile; and updated data from a Phase 1 study of CD19 NEX-T showing promising efficacy and safety in patients with severe, refractory autoimmune diseases.
The data presented at ASH reinforces BMS’s position as a leader in cell therapy. The continued development and refinement of existing therapies like Breyanzi, combined with the exploration of novel targets like GPRC5D with arlo-cel, and the expansion into new therapeutic areas like autoimmune diseases with CD19 NEX-T, positions BMS to significantly impact the landscape of cancer and autoimmune disease treatment. The positive clinical results and high manufacturing success rates suggest a promising future for these therapies, potentially offering new treatment paradigms and improved outcomes for patients with a range of serious diseases.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
